BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30587936)

  • 1. Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer.
    Brett J; Boulton M; Watson E
    Patient Prefer Adherence; 2018; 12():2639-2647. PubMed ID: 30587936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remote Monitoring App for Endocrine Therapy Adherence Among Patients With Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Graetz I; Hu X; Kocak M; Krukowski RA; Anderson JN; Waters TM; Curry AN; Robles A; Paladino A; Stepanski E; Vidal GA; Schwartzberg LS
    JAMA Netw Open; 2024 Jun; 7(6):e2417873. PubMed ID: 38935379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THRIVE intervention development: using participatory action research principles to guide a mHealth app-based intervention to improve oncology care.
    Anderson JN; Krukowski RA; Paladino AJ; Graff JC; Schwartzberg L; Curry AN; Vidal GA; Jones TN; Waters TM; Graetz I
    J Hosp Manag Health Policy; 2021 Mar; 5():. PubMed ID: 34308256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer.
    Paladino AJ; Anderson JN; Krukowski RA; Waters T; Kocak M; Graff C; Blue R; Jones TN; Buzaglo J; Vidal G; Schwartzberg L; Graetz I
    BMC Health Serv Res; 2019 Dec; 19(1):977. PubMed ID: 31856812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence.
    Brett J; Boulton M; Fenlon D; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery BA; Morgan A; Morris C; Watson EK
    Patient Prefer Adherence; 2018; 12():291-300. PubMed ID: 29497284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
    Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
    Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy.
    Green SMC; French DP; Graham CD; Hall LH; Rousseau N; Foy R; Clark J; Parbutt C; Raine E; Gardner B; Velikova G; Moore SJL; Buxton J; ; Smith SG
    BMC Health Serv Res; 2022 Aug; 22(1):1081. PubMed ID: 36002831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the HT&Me intervention to support women with breast cancer to adhere to adjuvant endocrine therapy and improve quality of life.
    Stewart SF; Slodkowska-Barabasz J; McGeagh L; Moon Z; Brett J; Wells M; Brown MC; Turner M; Horne R; Fenlon D; Rehman F; Cain H; Donnelly P; Harmer V; Turner L; Rose J; Sharp L; Watson E;
    Breast; 2023 Aug; 70():32-40. PubMed ID: 37300986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Women's Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions.
    Humphries B; Collins S; Guillaumie L; Lemieux J; Dionne A; Provencher L; Moisan J; Lauzier S
    Pharmacy (Basel); 2018 Jun; 6(2):. PubMed ID: 29890738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
    Toledo G; Ochoa CY; Farias AJ
    Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
    Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
    Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.
    Toivonen KI; Oberoi D; King-Shier K; Piedalue KL; Rash JA; Carlson LE; Campbell TS
    Curr Oncol; 2021 Jul; 28(4):2496-2515. PubMed ID: 34287250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results.
    Assan O; Memoli V; Guillaumie L; Turcotte V; Lemay M; Dionne A; Lemieux J; Provencher L; Gotay C; de Bruin M; Guénette L; Lauzier S
    J Cancer Surviv; 2024 May; ():. PubMed ID: 38702555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors.
    Bright EE; Finkelstein LB; Nealis MS; Genung SR; Wrigley J; Gu HCJ; Schmiege SJ; Arch JJ
    J Clin Oncol; 2023 Oct; 41(28):4548-4561. PubMed ID: 37531593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Survey of Potentially Modifiable Patient-Level Factors Associated with Self-Report and Objectively Measured Adherence to Adjuvant Endocrine Therapies After Breast Cancer.
    Toivonen KI; Carlson LE; Rash JA; Campbell TS
    Patient Prefer Adherence; 2021; 15():2039-2050. PubMed ID: 34552322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
    BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.
    En-Nasery-de Heer S; Tromp VNMF; Westerman MJ; Konings I; Beckeringh JJ; Boons CLM; Timmers L; Hugtenburg JG
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13749. PubMed ID: 36300863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Telushi E; Lapitan E; Nightingale G; Miller S; Wen KY
    Res Sq; 2023 Jan; ():. PubMed ID: 36778385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach.
    Janssen AM; Dam J; Prins J; Buffart LM; de Bruin M
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13721. PubMed ID: 36263723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.